^
Association details:
| Biomarker: | BCL2L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + pelcitoclax (APG-1252) (Bcl2 inhibitor, Bcl-xL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1317MO - Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC)
Published date:
10/16/2023
Excerpt:
For pts with TP53 and EGFR-positive mutations in EC-3, 13/16 (81.3%) PRs were observed, and the median progression-free survival (range) was 16.39 (8.11-NR) months. Preliminary biomarker data from pts in EC-2 suggested that high BCL-xL expression was associated with antitumor efficacy...Based on these findings, pelcitoclax plus osimertinib is of potential clinical interest to improve outcomes of pts with TP53- and EGFR-mutant NSCLC.
Trial ID:
